Which company produces Imatinib and an introduction to drug quality assurance

Imatinib (Imatinib) was originally developed and produced by the Swiss pharmaceutical giant Novartis (Novartis) and is one of the first targeted therapies in the world. Since its approval at the end of the 20th century, imatinib has played an important role in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). As an original drug manufacturer, Novartis has a complete R&D, production and quality management system to ensure that drugs meet strict standards in terms of safety and effectiveness.

Imatinib strictly follows the international pharmaceutical manufacturing quality management regulations (GMP) during the production process, covering all aspects of raw material procurement, production technology, packaging, storage and transportation. Each batch of drugs must undergo strict quality control testing, including key indicators such as drug purity, content, stability, and dissolution, to ensure that the ingredients and dosage of each drug are consistent with standards to ensure clinical efficacy.

In China, many companies have obtained production or generic licenses for imatinib. Some pharmaceutical companies produce domestic generic drugs at relatively lower prices. The common specifications are 100mg*60 tablets, and the price is about six to seven hundred yuan. Although it is a generic drug, it must meet the approval requirements of the State Food and Drug Administration in terms of drug ingredients, quality standards and efficacy, and is highly consistent with the original drug, providing patients with more affordable and accessible options.

Whether it is an imported original drug or a domestic generic drug, imatinib must undergo strict quality testing and supervision to ensure the safety and reliability of the drug. Patients should purchase drugs through regular hospitals and pharmacies when using them, and avoid obtaining drugs through informal channels to reduce counterfeit drugs and quality risks. In clinical use, it is recommended to take it according to the treatment course and dosage under the guidance of a doctor, and to regularly review blood indicators to ensure the therapeutic effect and drug safety.

Reference materials:https://www.drugs.com/